Full Text View
Tabular View
No Study Results Posted
Related Studies
Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill (VASTVALUS)
This study has been completed.
Study NCT01073800   Information provided by University of Alberta

First Received on July 20, 2009.   Last Updated on December 15, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myocardial Infarction
Stroke
Renal Failure
Additional conditions recognized in this trial
Critical Illness
Infarction
Renal Insufficiency
More general conditions related to this trial
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Disease Attributes
Heart Diseases
Ischemia
Kidney Diseases
Myocardial Ischemia
Necrosis
Nervous System Diseases
Pathologic Processes
Urologic Diseases
Vascular Diseases
Interventions listed in this trial
atorvastatin 80 mg per os daily
placebo
Additional drug interventions recognized in this trial
Atorvastatin
More general drug interventions related to this trial
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University of Alberta


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services